Insmed Inc (INSM)vsSellas Life Sciences Group Inc (SLS)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
SLS
Sellas Life Sciences Group Inc
$5.30
+6.11%
HEALTHCARE · Cap: $897.01M
Smart Verdict
WallStSmart Research — data-driven comparison
SLS leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
SLS
Avoid17
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Trading at 11.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : SLS
SLS has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : SLS
The primary concerns for SLS are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while SLS is a value play — different risk/reward profiles.
SLS carries more volatility with a beta of 2.21 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
SLS generates stronger free cash flow (-5M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 17/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Sellas Life Sciences Group Inc
HEALTHCARE · BIOTECHNOLOGY · USA
SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications of cancer in the United States. The company is headquartered in New York, New York.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?